Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/197341
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Palafox Sánchez, Marta | - |
dc.contributor.author | Monserrat Vicente, Laia | - |
dc.contributor.author | Bellet Ezquerra, Meritxell | - |
dc.contributor.author | Villacampa, Gullermo | - |
dc.contributor.author | González Pérez, Abel | - |
dc.contributor.author | Oliveira, Mafalda | - |
dc.contributor.author | Brasó Maristany, Fara | - |
dc.contributor.author | Ibrahimi, Nusaibah | - |
dc.contributor.author | Kannan, Srinivasaraghavan | - |
dc.contributor.author | Mina, Leonardo | - |
dc.contributor.author | Herrera Abreu, Maria Teresa | - |
dc.contributor.author | Odena, Andreu | - |
dc.contributor.author | Sánchez Guixé, Mònica | - |
dc.contributor.author | Capelán, Marta | - |
dc.contributor.author | Azaro, Analía | - |
dc.contributor.author | Bruna, Alejandra | - |
dc.contributor.author | Rodriguez, Olga | - |
dc.contributor.author | Guzmán, Marta | - |
dc.contributor.author | Grueso, Judit | - |
dc.contributor.author | Viaplana, Cristina | - |
dc.contributor.author | Hernandez, Javier | - |
dc.contributor.author | Su, Faye | - |
dc.contributor.author | Lin, Kui | - |
dc.contributor.author | Clarke, Robert | - |
dc.contributor.author | Caldas, Carlos | - |
dc.contributor.author | Arribas, Joaquín | - |
dc.contributor.author | Michiels, Stefan | - |
dc.contributor.author | García Sanz, Alicia | - |
dc.contributor.author | Turner, Nicholas, 1951- | - |
dc.contributor.author | Prat Aparicio, Aleix | - |
dc.contributor.author | Nuciforo, Paolo | - |
dc.contributor.author | Dienstmann, Rodrigo | - |
dc.contributor.author | Verma, Chandra S | - |
dc.contributor.author | López Bigas, Núria | - |
dc.contributor.author | Scaltriti, Maurizio | - |
dc.contributor.author | Arnedos, Monica | - |
dc.contributor.author | Saura, Cristina | - |
dc.contributor.author | Serra Elizalde, Violeta | - |
dc.date.accessioned | 2023-04-27T10:26:45Z | - |
dc.date.available | 2023-04-27T10:26:45Z | - |
dc.date.issued | 2022-09-07 | - |
dc.identifier.issn | 2041-1723 | - |
dc.identifier.uri | http://hdl.handle.net/2445/197341 | - |
dc.description.abstract | CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n?=?37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n?=?89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies.© 2022. The Author(s). | - |
dc.format.extent | 20 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1038/s41467-022-32828-6 | - |
dc.relation.ispartof | Nature Communications, 2022, vol. 13 | - |
dc.relation.uri | https://doi.org/10.1038/s41467-022-32828-6 | - |
dc.relation.uri | https://doi.org/10.1038/s41467-022-34580-3 | - |
dc.rights | cc by (c) Palafox Sánchez, Marta et al., 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Resistència als medicaments | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Drug resistance | - |
dc.title | High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-04-26T12:53:15Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 9329495 | - |
dc.identifier.idimarina | 9332525 | - |
dc.identifier.pmid | 36071033 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
High p16 expression and heterozygous RB1_NatureCommunications.pdf | 4.17 MB | Adobe PDF | View/Open | |
Correction_High p16 expression and heterozygous RB1 loss_NatureCommunications.pdf | Author Correction | 526.7 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License